×

Do you want to link to this External Site and leave Amgen.co.uk?

YOU ARE NOW LEAVING THIS WEBSITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this Amgen Site outside the UK and leave Amgen.co.uk?

YOU ARE NOW LEAVING THIS WEBSITE. Amgen Limited and Amgen Ireland Limited takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Please note, this page is intended for UK healthcare professionals. By clicking to enter this page you are confirming that you are a UK healthcare professional.

×

Do you want to link to this Amgen Site and leave Amgen.co.uk?

Please note this site is only intended for UK Healthcare professionals and UK patients that have been prescribed Prolia®

YOU ARE NOW LEAVING THIS WEBSITE.

Joint Working Initiatives


Title Identification of patients with vertebral fractures from CT scans taken during the assessment of other conditions.
Organisations Involved Nottingham University Hospitals NHS Trust and Amgen. The opportunistic vertebral fracture case finding service (ASPIRE) was developed by Optasia Medical Limited.
Joint Working Project
Description

The overall aim of the joint working project between Nottingham University Hospitals NHS Trust and Amgen is to identify vertebral fractures of patients having CT scans whilst in hospital for other conditions. These patients will then be referred to the Fracture Liaison Service (FLS) to receive appropriate management.

Expected outcomes

The joint working project is designed to support the implementation of The National Osteoporosis Clinical Guideline Group for the effective identification of vertebral fractures.

Key outputs from the joint working project will include the following:

  • improvements in identification of patients with vertebral fractures
  • improvement in quality of life for patients with vertebral fracture, via referral to a FLS to minimize the risk of future fracture

UKIE-NPC-162-1017-056268 October 2017


 

Title Falls and Fracture Prevention, a Population Approach
Organisations Involved Academic Health Science Network for the North East and North
Cumbria (AHSN-NENC) and Amgen Ltd (delivered by Interface Clinical
Services)
Joint Working Project
Description

The overall aim of the Academic Health Science Network for the North
East and North Cumbria, in collaboration with Clinical Commissioning Groups, GP Practices, Interface Clinical Services (ICS) and Amgen is to support targeted fracture risk assessment and bone sparing medication review at primary care level. By identifying patients at high risk of fracture, evaluate their medications, educate and treat them, with the sole aim of future fracture prevention.

Expected outcomes

The Joint working project is designed to support the adoption of NICE CG 146, and support the uptake and adoption of NICE TA 160 and NICE TA 161. It is expected this process will support the early adoption of the revised NICE musculoskeletal guidance for osteoporosis.

Key outputs from the joint working project will include the following:

  • Patient education around osteoporosis; including the importance of a healthy diet and exercise.
  • Optimisation of treatment and support for primary and secondary fracture prevention
  • Support for GP practices to achieve the QOF osteoporosis indicators
  • Establishment of a process and educational legacy for primary care NHS organisations to support sustained quality improvement in the management of patients with osteoporosis
  • Availability of a report to show cost savings in terms of fragility fractures and social care.

UKIE-NPC-162-0817-053438 August 2017


 

Title
Optimising the care pathway for patients – moving care closer to the patient’s home
Organisations Involved
University College London Hospital NHS Foundation Trust (UCLH) and Amgen Ltd.
Joint Working Project Description
As part of the Cancer Vanguard workstream Optimising the use of cancer medicines, UCLH and Amgen are working in partnership to optimise the Systemic Anti Cancer Therapy (SACT) care pathway to enable appropriate patients to receive their treatment closer to home.
Expected Outcomes
This initiative will develop an algorithm to assess the suitability of various Systemic Anti Cancer Therapy (SACT) to be administered in a community care setting.

 The project team will evaluate different community –based service options with the aim of identifying the optimal pathway for UCLH. Optimisation of out of hospital treatment is anticipated to allow patient care to be delivered closer to home and as a result to reduce pressure within the oncology suites of the hospital trust.

UKIE-NPC-CARF-0817-053021 August 2017


 

Title
Falls and Fracture Prevention, a Population Approach
Organisations Involved
North West Innovation Agency and North Coast AHSN and Amgen Ltd (delivered by Interface Clinical Services)
Joint Working Project Description

The overall aim of the North West Innovation Agency and North Coast ASHN, in collaboration with Clinical Commissioning Groups, GP Practices, Interface Clinical Services (ICS), and Amgen is to reduce the risk of falls and fractures. By using targeted fracture risk assessment and Bone Sparing Medication Review in patients with Osteoporosis and Fragility fractures in Primary Care, to increase awareness of the importance of fracture prevention and improve primary and secondary prevention of osteoporosis locally.

Expected Outcomes

The Joint working project is designed to support the adoption of NICE CG 146, and support the uptake and adoption of NICE TA 160 and NICE TA 161. It is expected this process will support the early adoption of the revised NICE musculoskeletal guidance for osteoporosis.

Key outputs from the joint working project will include the following:

  • Patient education around Osteoporosis; including the importance of a healthy diet and exercise
  • Optimisation of treatment and support for primary and secondary fracture prevention
  • Support for GP practices to achieve the QOF osteoporosis indicators 
  • Establishment of a process and educational legacy for primary care NHS organisations to support sustained quality improvement in the management of patients with osteoporosis 
  • Availability of a report to show estimated cost savings in terms of fragility and social care

UKIE-NPC-162-1017-056814 December 2017


 

Title
Improving the identification and treatment of patients with Familial Hypercholesterolemia (FH) in primary care.
Organisations Involved
Academic Health Science Network for the North East and North Cumbria (AHSN-NENC) and Amgen Ltd in collaboration with Clinical Commissioning Groups, GP Practices and PRIMIS.
Joint Working Project Description

The overall aims of this project are to:

  • Identify patients at high risk of Familial Hypercholesterolemia (FH), evaluate medications, educate and treat patients with the sole aim of reducing excess coronary heart disease risk and premature mortality associated with Familial Hypercholesterolemia (FH).
  • Increase the utilisation of the genetic screening programme across the AHSN footprint through better patient identification.
  • Improve the patient experience by providing more specialist care within primary care and ensure better utilisation and more appropriate referrals to the specialist service base with the NHS Trust.
To develop a Familial Hypercholesterolemia (FH) service model which can be scaled up nationally.
Expected Outcomes

The expected outcomes from this project are as follows:

  • A written document to inform the treatment of Familial Hypercholesterolemia (FH) patients in primary care including information on implementing patient identification using a Familial Hypercholesterolemia (FH) patient identification tool and clinical review at a practice level.
  • A toolkit to include training materials on Familial Hypercholesterolemia (FH) and its treatment for healthcare professionals in primary care and the use of the Familial Hypercholesterolemia (FH) patient identification tool.

The project incorporates the principles of improved patient education, medicines optimisation and treatment close to home.        

 

UKIE-NPC-145-0318-062450 April 2018


 

Title
Lipid Commissioning for Value
Organisations Involved
Innovation Agency, North West Coast Academic Health Science Network, Salvera Services Ltd & Amgen Ltd
Joint Working Project Description

To develop an optimal clinical & commissioning pathway for people with cardiovascular disease (CVD) due to atherosclerosis and suspected familial hypercholesterolemia (FH), which will be piloted across a number of practices in the North West Coast Strategic Clinical Network geography.

Expected Outcomes

The joint working project is designed to improve identification of patients with cardiovascular disease (CVD) or familial hypercholesterolemia (FH) and to improve the pathways of care for these patients

The key deliverables from the project:

  • Development of an optimal clinical and commissioning pathway for people with cardiovascular disease (CVD) caused by atherosclerosis and suspected familial hypercholesterolemia (FH)
  • Establish and deliver a proof of concept pilot for the clinical pathway across 10 practices within the geography. This will include a current service review as well as implementation of the clinical pathway
  • Write a formal evaluation of the pilot project.

UKIE-NPC-145-1117-057526 April 2018 




Title
Quality Improvement Project - Introduction of a novel pathway to improve lipid control in post transient ischemic attack (TIA), stroke and patients with Peripheral vascular disease (PVD)
Organisations Involved
University Hospitals of Leicester NHS Trust (UHL) and Amgen UK.
Joint Working Project Description

The aim of the joint working project to develop a clinical pathway for optimisation of lipid levels in patients with TIA, stroke or PVD patients at UHL that if successful could be adopted on a UK wide scale.

Expected Outcomes

The joint working project is designed to improve lipid management services for patients by developing a care pathway which aims to:

  • Reduce variation in care of lipid management
  • Implement a cross departmental approach to lipid management
  • Improve medicine optimisation of lipid medication
  • Demonstrate potential financial benefits through improvements in care

The key out puts from the project are to:

Develop an optimal clinical pathway for patients post TIA, stroke and patients with PVD.

Complete a health economic benefit analysis of the above pathway

UKIE-NPC-145-0618-065600a June 2018 



Title
Development of Educational Resource & Identification of High Risk CVD/FH in Irish Primary Care setting.
Organisations Involved
The Irish College of General Practitioners (ICGP) and Amgen Ireland Ltd.
Joint Working Project Description

The development of identification processes for patients at high risk of premature cardiovascular disease (CVD) and possible Familial Hypercholesterolemia (FH) in the Irish Primary Care setting

Expected Outcomes
The aim of this joint working project is a partnership between Amgen and the ICGP to raise awareness amongst GPs of patients at high risk of premature CVD/ FH in the general practice setting. 
 
The key deliverables from the project: 
 
• Develop an educational resource to raise awareness amongst GPs of high risk CVD/ FH and detecting this disease.
• Create a sample case finding audit tool to be placed on the ICGP audit site and promoted by ICGP in the professional competence audit cycle year 2018-2019 to support identification of high risk CVD/FH patients.
• Write a formal evaluation of the pilot project including aggregate data from a sample of practices nationally that will better inform future system changes for patient identification and referral networks.

UKIE-CC-145-0718-066560a July 2018 



Title
Identification of patients with vertebral fractures from CT scans taken during the assessment of other conditions.
Organisations Involved
Bradford Teaching Hospitals NHS Foundation Trust and Amgen. The opportunistic vertebral fracture case finding service (ASPIRE) was developed by Optasia Medical Limited.
Joint Working Project Description

The overall aim of the joint working project between Bradford Teaching Hospitals NHS Foundation Trust and Amgen is to identify vertebral fractures of patients having CT scans whilst in hospital for other conditions. These patients will then be referred to the Fracture Liaison Service (FLS) to receive appropriate management.

Expected Outcomes
The joint working project is designed to support the implementation of The National Osteoporosis Clinical Guideline Group for the effective identification of vertebral fractures. 
 
Key outputs from the joint working project will include the following:

• improvements in identification of patients with vertebral fractures.

• improvement in quality of life for patients with vertebral fracture, via referral to a FLS to minimize the risk of future fracture.

UKIE-NPC-162-0718-066085 July 2018



Title
The impact of the introduction of trastuzumab biosimilar on patients and NHS services
Organisations Involved
Amgen Ltd and The Christie Hospital
Joint Working Project Description

The project is to conduct a detailed review of the Christie’s process and patient experience of transition to a trastuzumab biosimilar or initiation of a trastuzumab biosimilar. The aim will be to a) ensure that patients experience a smooth transition and are able to feedback on every element of the process b) collect clinician feedback on the transition process and identify factors for change. Results from this project will facilitate improved process and outcomes for other patients coming into the system both for this trastuzumab biosimilar transition and also for future biosimilars that are expected to emerge.

As a result of the project, the Christie will establish a system whereby they can monitor and assess all patients either transferred onto trastuzumab biosimilar or commenced on trastuzumab biosimilar.

Expected Outcomes

The project will:

• Gather the views and opinions of clinical staff, to inform and support the strategies used for the introduction of future biosimilars

• Gather useful insights from patients about information provided to them during the transitioning period

• Enable a more streamlined experience for the patient to be established

• Identify patients who want to stay on the originator and understand their rationale

• Identify the patients who were transferred back to originator and the reasoning

UKIE-NPC-KJTI-1118-069634a November 2018